A poster presentation at the 96th annual meeting of the American Association for Cancer Research (AACR) in California, reviewed the results of a study designed to explore the activity of satraplatin in several drug-resistant human tumor cell lines, including those resistant to taxanes, mitoxantrone, etoposide, camptothecin and cisplatin.
The study results showed that the pre-treated cells remained sensitive to satraplatin, thereby providing a rationale for evaluation of satraplatin in patients who have progressed on these other cancer treatments.
In addition, researchers evaluated the effect of a combination of Taxotere (docetaxel) and satraplatin on prostate cancer cells. The results indicated that, when these cells are exposed first to Taxotere and then to satraplatin, there appears to be a synergistic effect. When the cells were exposed to the two compounds at the same time, only an additive effect was observed.
The results are supportive of studying a combination treatment of Taxotere and satraplatin in human clinical studies, including evaluating sequential regimens. GPC Biotech plans to initiate a phase I trial evaluating a combination treatment of satraplatin and Taxotere in the next few months.